Induction treatment prior to surgery in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010
Indication and results of surgery in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010
Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Intraoperative photodinamic therapy as a part of combined radical treatment for stage III NSCLC Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011
Phase II trial on neoadjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment Year: 2003
Postoperative adjuvant treatment in stage III NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
Chemoradiotherapy with or without surgical resection for stage III NSCLC Source: Breathe 2010; 6: 275 Year: 2010
Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery Source: ISSN=ISSN 1810-6838, ISBN=, page=279 Year: 2008
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? Source: ERJ Open Res, 6 (1) 00159-2019; 10.1183/23120541.00159-2019 Year: 2020
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Role of adjuvant/neoadjuvant treatment in stage I NSCLC Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC) Year: 2014